tetano
Editor, Senior Moderator
J Atheroscler Thromb
. 2020 Oct 15.
doi: 10.5551/jat.58297. Online ahead of print.
Safety and Efficacy of Simultaneous Inoculations of Pneumococcal and Influenza Vaccines in Patients with Coronary Artery Disease
Kazunori Shimada[SUP] 1 2 [/SUP], Hiroaki Morinaga[SUP] 3 [/SUP], Takashi Kiyanagi[SUP] 4 [/SUP], Tetsuro Miyazaki[SUP] 1 [/SUP], Miho Nishitani-Yokoyama[SUP] 1 [/SUP], Iwao Okai[SUP] 1 [/SUP], Hiroshi Tamura[SUP] 1 [/SUP], Hakuoh Konishi[SUP] 1 [/SUP], Takeshi Kurata[SUP] 1 [/SUP], Katsumi Miyauchi[SUP] 1 [/SUP], Hiroyuki Daida[SUP] 1 2 5 [/SUP]
Affiliations
Abstract
Aim: Pneumococcal and influenza infections can cause serious morbidity and mortality in patients with cardiovascular diseases. The purpose of this study was to investigate the safety and efficacy of simultaneous inoculations of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and trivalent influenza vaccine (TIV) in patients with coronary artery disease (CAD).
Methods: This was a prospective, randomized, single-blind, placebo-controlled study. A total of 40 patients with CAD were randomly assigned to the TIV＋PPSV23 (simultaneous inoculations of TIV and PPSV23) and TIV＋Placebo (inoculations of TIV and placebo) groups. Primary outcomes were the safety of simultaneous vaccinations and the changing of circulating cardiovascular biomarkers before, at 4-, and at 12-weeks after vaccinations.
Results: The baseline characteristics between the two groups were identical. The prevalence of injection-site pain, swelling, and reddening were 47%, 37%, and 37% in the TIV＋PPSV23 group, and 10%, 5%, and 0% in the TIV＋Placebo group, respectively. All reactions were self-limited. Body temperature ＞37.0℃ or serious injection-related reaction was not observed. The levels of white blood cells, high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, pentraxin-3, and malondialdehide-modified low-density lipoprotein (LDL), were not significantly different between the two groups before and after vaccinations. The levels of anti-oxidized LDL were significantly and step-wisely decreased from baseline, to 4-, and 12-weeks vaccinations in the both groups. No significant changes of other markers were observed in both groups at each time point.
Conclusion: Simultaneous inoculations of TIV and PPSV23 were safety in patients with CAD, suggesting that dual vaccinations can be considered even in patients with CAD.
Keywords: 23-valent pneumococcal polysaccharide vaccine; Coronary artery disease; Inflammation; Influenza vaccine; Oxidized low-density lipoprotein.
. 2020 Oct 15.
doi: 10.5551/jat.58297. Online ahead of print.
Safety and Efficacy of Simultaneous Inoculations of Pneumococcal and Influenza Vaccines in Patients with Coronary Artery Disease
Kazunori Shimada[SUP] 1 2 [/SUP], Hiroaki Morinaga[SUP] 3 [/SUP], Takashi Kiyanagi[SUP] 4 [/SUP], Tetsuro Miyazaki[SUP] 1 [/SUP], Miho Nishitani-Yokoyama[SUP] 1 [/SUP], Iwao Okai[SUP] 1 [/SUP], Hiroshi Tamura[SUP] 1 [/SUP], Hakuoh Konishi[SUP] 1 [/SUP], Takeshi Kurata[SUP] 1 [/SUP], Katsumi Miyauchi[SUP] 1 [/SUP], Hiroyuki Daida[SUP] 1 2 5 [/SUP]
Affiliations
- PMID: 33055462
- DOI: 10.5551/jat.58297
Abstract
Aim: Pneumococcal and influenza infections can cause serious morbidity and mortality in patients with cardiovascular diseases. The purpose of this study was to investigate the safety and efficacy of simultaneous inoculations of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and trivalent influenza vaccine (TIV) in patients with coronary artery disease (CAD).
Methods: This was a prospective, randomized, single-blind, placebo-controlled study. A total of 40 patients with CAD were randomly assigned to the TIV＋PPSV23 (simultaneous inoculations of TIV and PPSV23) and TIV＋Placebo (inoculations of TIV and placebo) groups. Primary outcomes were the safety of simultaneous vaccinations and the changing of circulating cardiovascular biomarkers before, at 4-, and at 12-weeks after vaccinations.
Results: The baseline characteristics between the two groups were identical. The prevalence of injection-site pain, swelling, and reddening were 47%, 37%, and 37% in the TIV＋PPSV23 group, and 10%, 5%, and 0% in the TIV＋Placebo group, respectively. All reactions were self-limited. Body temperature ＞37.0℃ or serious injection-related reaction was not observed. The levels of white blood cells, high-sensitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, pentraxin-3, and malondialdehide-modified low-density lipoprotein (LDL), were not significantly different between the two groups before and after vaccinations. The levels of anti-oxidized LDL were significantly and step-wisely decreased from baseline, to 4-, and 12-weeks vaccinations in the both groups. No significant changes of other markers were observed in both groups at each time point.
Conclusion: Simultaneous inoculations of TIV and PPSV23 were safety in patients with CAD, suggesting that dual vaccinations can be considered even in patients with CAD.
Keywords: 23-valent pneumococcal polysaccharide vaccine; Coronary artery disease; Inflammation; Influenza vaccine; Oxidized low-density lipoprotein.